ClinicalTrials.gg
TerminatedNCT04396106Updated Mar 9, 2023Results posted

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

A Phase 2 interventional study of AT-527 and Placebo in COVID-19, sponsored by Atea Pharmaceuticals, Inc.. Terminated at 37 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-09.

Sponsored by Atea Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Study closed out early due to evolving COVID-19 standard of care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
677th of 1,321
83 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
343rd of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 677th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 343rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate the safety, tolerability, antiviral activity and efficacy of AT-527 in adult subjects ≥18 years of age with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or matching placebo tablets to be administered orally for 5 days. Part A will evaluate an AT-527 dose of 550 mg BID and Part B will evaluate a second dose of AT-527 (1100 mg BID). Local supportive standard of care (SOC) will be allowed for all subjects. Efficacy, antiviral activity and safety observations will be compared for treatment with active AT-527 tablets vs. placebo tablets.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Hospitalized or in a hospital-affiliated confinement facility
  • SARS-CoV-2 positive
  • Initial COVID-19 symptom onset within 5 days prior to Screening
  • SpO2 ≥ 93% on room air or requires ≤ 2L/min oxygen by nasal cannula or mask to maintain SpO2 ≥ 93%
  • Must also have a history of at least one of the following known risk factors for poor outcomes: obesity (>30), hypertension, diabetes or asthma.

Key Exclusion Criteria:

  • Severe or critical COVID-19 illness: RR ≥30, HR ≥125, SpO2 \<93% on room air or requires >2L/min oxygen by nasal cannula or mask to maintain SpO2 ≥93%, systolic blood pressure \< 90 mm Hg, diastolic blood pressure \< 60 mm Hg or PaO2/FiO2 \<300
  • Requires mechanical ventilation
  • Lobar or segmental consolidation on chest imaging.
  • Treatment with other drugs thought to possibly have activity against SARS-CoV-2
  • or AST > 5 x (ULN)
  • Female subject is pregnant or breastfeeding
  • Has received or is expected to receive any dose of a SARS-CoV-2 vaccine before the Day 14 visit (Part B).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
83 participants (actual)

Study arms

  • Active comparator
    AT-527 - 550 mg BID

    Part A

    Drug: AT-527

  • Placebo comparator
    Placebo for 550 mg BID

    Part A

    Other: Placebo

  • Active comparator
    AT-527 - 1100 mg BID

    Part B

    Drug: AT-527

  • Placebo comparator
    Placebo for 1100 mg BID

    Part B

    Other: Placebo

Interventions

  • DrugAT-527

    One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days

  • OtherPlacebo

    One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days

  • DrugAT-527

    Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days

  • OtherPlacebo

    Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days

06

What researchers measure

Primary outcomes

  1. Proportions (Active vs. Placebo) of Subjects With Progressive Respiratory Insufficiency (PRI) on or Before Day 14.

    Progressive respiratory insufficiency defined as a ≥ 2-tier increase in respiratory support methods required to maintain satisfactory oxygenation (SpO2 ≥ 93%), using the 6-tier hierarchical scale of respiratory support methods, within the 14-day study period. Level 1:Normal oxygenation on room air (SpO2 ≥93), no need for supplemental O2 Level 2:Persistent hypoxemia on room air (SpO2 \<93) with requirement for low-level supplemental O2 by nasal cannula/mask (up to 2L/min) to maintain SpO2 ≥93 Level 3:Requirement for higher levels of passive supplemental O2 by nasal cannula or mask (≥2 L/min) to maintain SpO2 ≥93 Level 4:Requirement for oxygenation by positive-pressure devices Level 5:Required invasive respiratory support (intubated mechanical ventilation or ECMO) Level 6:Death

    Time frame: Day 14

Secondary outcomes

  1. Change From Baseline in Amount of SARS-CoV-2 Virus RNA by Nasopharyngeal Swab

    Change in the viral load as measured by swab of the upper part of the pharynx.

    Time frame: Through Day 14

07

Results

Posted Mar 9, 2023
Limitations and caveats
Study was prematurely discontinued. At the time of study discontinuation, only 2 subjects were enrolled in Part B and both received placebo.

Participant flow

Participant flow — Overall Study
MilestoneAT-527 - 550 mg BIDPlacebo for 550 mg BIDAT-527 - 1100 mg BIDPlacebo for 1100 mg BID
Started414002
Completed373701
Not completed4301

Outcome measures

PrimaryProportions (Active vs. Placebo) of Subjects With Progressive Respiratory Insufficiency (PRI) on or Before Day 14.

Progressive respiratory insufficiency defined as a ≥ 2-tier increase in respiratory support methods required to maintain satisfactory oxygenation (SpO2 ≥ 93%), using the 6-tier hierarchical scale of respiratory support methods, within the 14-day study period. Level 1:Normal oxygenation on room air (SpO2 ≥93), no need for supplemental O2 Level 2:Persistent hypoxemia on room air (SpO2 \<93) with requirement for low-level supplemental O2 by nasal cannula/mask (up to 2L/min) to maintain SpO2 ≥93 Level 3:Requirement for higher levels of passive supplemental O2 by nasal cannula or mask (≥2 L/min) to maintain SpO2 ≥93 Level 4:Requirement for oxygenation by positive-pressure devices Level 5:Required invasive respiratory support (intubated mechanical ventilation or ECMO) Level 6:Death

Time frame:
Day 14
Reported as:
Count of participants · Participants
Proportions (Active vs. Placebo) of Subjects With Progressive Respiratory Insufficiency (PRI) on or Before Day 14.
ParticipantsAT-527 - 550 mg BIDPlacebo for 550 mg BIDAT-527 - 1100 mg BIDPlacebo for 1100 mg BID
Proportions (Active vs. Placebo) of Subjects With Progressive Respiratory Insufficiency (PRI) on or Before Day 14.34—0
Statistical analysis
  • AT-527 - 550 mg BID vs Placebo for 550 mg BID · Cochran-Mantel-Haenszel · p = 0.721
SecondaryChange From Baseline in Amount of SARS-CoV-2 Virus RNA by Nasopharyngeal Swab

Change in the viral load as measured by swab of the upper part of the pharynx.

Time frame:
Through Day 14
Reported as:
Mean · log10 copies/mL
Change From Baseline in Amount of SARS-CoV-2 Virus RNA by Nasopharyngeal Swab
log10 copies/mLAT-527 - 550 mg BIDPlacebo for 550 mg BIDAT-527 - 1100 mg BIDPlacebo for 1100 mg BID
Change from baseline to Day 2-0.55 ± 1.175-0.02 ± 1.838—-1.37 ± 1.57
Change from baseline to Day 5-1.00 ± 1.316-0.80 ± 1.853—-2.51 ± 0.66
Change from baseline to Day 8-1.64 ± 1.534-1.38 ± 1.281—-3.78 ± 1.39
Change from baseline to Day 10-1.72 ± 1.734-2.26 ± 1.452—-4.78 ± 2.13
Change from baseline to Day 12-2.13 ± 2.065-2.08 ± 1.584—-4.78 ± 2.13
Change from baseline to Day 14-2.61 ± 1.873-2.26 ± 1.747—-4.13 ± 1.21

Adverse events

Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AT-527 - 550 mg BID0/40 (0%)5/40 (12.5%)24/40 (60%)
Placebo for 550 mg BID2/40 (5%)3/40 (7.5%)23/40 (57.5%)
AT-527 - 1100 mg BID———
Placebo for 1100 mg BID1/2 (50%)1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAT-527 - 550 mg BIDPlacebo for 550 mg BIDAT-527 - 1100 mg BIDPlacebo for 1100 mg BID
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/400/40—1/2
Oxygen saturation decreasedInvestigations2/401/40—0/2
Abdominal abscessInfections and infestations1/400/40—0/2
Acute kidney injuryRenal and urinary disorders0/401/40—0/2
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/400/40—0/2
COVID-19 pneumoniaInfections and infestations0/401/40—0/2
Haemodynamic instabilityVascular disorders0/401/40—0/2
Hyperglycaemic hyperosmolar nonketotic syndromeMetabolism and nutrition disorders1/400/40—0/2
PneumoniaInfections and infestations0/401/40—0/2
Respiratory failureRespiratory, thoracic and mediastinal disorders0/401/40—0/2
Most frequent other events
Showing 10 of 19
Most frequent other events
EventAT-527 - 550 mg BIDPlacebo for 550 mg BIDAT-527 - 1100 mg BIDPlacebo for 1100 mg BID
UrticariaSkin and subcutaneous tissue disorders0/400/40—1/2
HepatitisHepatobiliary disorders0/400/40—1/2
HaemoptysisRespiratory, thoracic and mediastinal disorders0/400/40—1/2
N-terminal prohormone brain natriuretic peptide increasedInvestigations0/400/40—1/2
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/400/40—1/2
Blood triglycerides increasedInvestigations6/406/40—0/2
Alanine aminotransferase increasedInvestigations3/406/40—0/2
Blood cholesterol increasedInvestigations5/402/40—0/2
Aspartate aminotransferase increasedInvestigations2/403/40—0/2
DiarrhoeaGastrointestinal disorders2/403/40—0/2

Baseline characteristics

Intent-to-treat

Age, Continuous
Age, Continuous(years)AT-527 - 550 mg BIDPlacebo for 550 mg BIDAT-527 - 1100 mg BIDPlacebo for 1100 mg BIDTotal
Mean54.3 ± 11.0757.4 ± 8.33—33.5 ± 20.555.8 ± 9.88
Sex: Female, Male
Sex: Female, Male(Participants)AT-527 - 550 mg BIDPlacebo for 550 mg BIDAT-527 - 1100 mg BIDPlacebo for 1100 mg BIDTotal
Female1925—246
Male2215—037
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AT-527 - 550 mg BIDPlacebo for 550 mg BIDAT-527 - 1100 mg BIDPlacebo for 1100 mg BIDTotal
American Indian or Alaska Native00—00
Asian24—06
Native Hawaiian or Other Pacific Islander00—00
Black or African American63—09
White2932—263
More than one race21—03
Unknown or Not Reported20—02
08

Study locations

37 sites
  • Atea Study Site
    Scottsdale, Arizona 85258, United States
  • Atea Study Site
    Davis, California 95817, United States
  • Atea Study Site
    Los Angeles, California 90017, United States
  • Atea Study Site
    Washington, District of Columbia 20037, United States
  • Atea Study Site
    Orlando, Florida 32804, United States
  • Atea Study Site
    Atlanta, Georgia 30303, United States
  • Atea Study Site
    Chicago, Illinois 60611, United States
  • Atea Study Site
    Chicago, Illinois 60612, United States
  • Atea Study Site
    Boston, Massachusetts 02115, United States
  • Atea Study Site
    Butte, Montana 59701, United States
  • Atea Study Site
    Charlotte, North Carolina 28204, United States
  • Atea Study Site
    Cincinnati, Ohio 45219, United States
  • Atea Study Site
    Columbus, Ohio 43203, United States
  • Atea Study Site
    Charleston, South Carolina 29425, United States
  • Atea Study Site
    Columbia, South Carolina 29203, United States
  • Atea Study Site
    Rosario, Argentina
  • Atea Study Site
    Vicente Lopez, Argentina
  • Atea Study Site
    Brussels, Belgium
  • Atea Study Site
    Mechelen, Belgium
  • Atea Study Site
    Belo Horizonte, Brazil
  • Atea Study Site
    Brasília, Brazil
  • Atea Study Site
    Campo Largo, Brazil
  • Atea Study Site
    Porto Alegre, Brazil
  • Atea Study Site
    São Paulo, Brazil
  • Atea Study Site
    Cairo, Egypt
  • Atea Study Site
    Chisinau, Moldova, Republic of
  • Atea Study Site
    Bucharest, Romania
  • Atea Study Site
    Bloemfontein, South Africa
  • Atea Study Site
    Cape Town, South Africa
  • Atea Study Site
    Centurion, South Africa
  • Atea Study Site
    George, South Africa
  • Atea Study Site
    Worcester, South Africa
  • Atea Study Site
    Barcelona, Spain
  • Atea Study Site
    Madrid, Spain
  • Atea Study Site
    Pozuelo De Alarcón, Spain
  • Atea Study Site
    Brovary, Ukraine
  • Atea Study Site
    Kyiv, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Jan 2022, 19 months.

Results were first posted in Mar 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2020
First posted
May 20, 2020
StartActual
May 26, 2020
Primary completionActual
Jan 10, 2022
CompletionActual
Feb 28, 2022
Results first posted
Mar 9, 2023
Last update
Mar 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04396106
Responsible party
Sponsor
First posted
May 20, 2020
Start date
May 26, 2020
Primary completion
Jan 10, 2022
Completion
Feb 28, 2022
Results posted
Mar 9, 2023
Last update
Mar 9, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bemnifosbuvir

Start the discussion